Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Key Inclusion Criteria: * Adults over 18 years of age with a life expectancy of at least 3 months. * Histologically or cytologically confirmed stage IIIB or stage IV non-squamous NSCLC that has not been previously treated with systemic chemotherapy. * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.1). * Adequate hematologic, renal and hepatic function. * PT / INR ≤ 1.5 × ULN, aPTT ≤ 1.5 × ULN and D-dimer ≤ 3 × ULN. Key Exclusion Criteria: * Squamous cell, small cell, or mixed histology. * Known history of bleeding diathesis or coagulopathy. * Cavitary tumors or tumors abutting large blood vessels. * Bleeding: Clinically significant bleeding, such as gross hematuria, GI bleeding and hemoptysis, within 12 months of Screening. * Venous thromboembolic events (e.g., deep vein thrombosis or pulmonary thromboembolism) within 6 months of Screening. * Ongoing therapy with oral or parenteral anticoagulants. * Concurrent estrogens, anti-estrogens or progesterone compounds. * Grade 2 or higher peripheral neuropathy. * Radiotherapy within 2 weeks preceding Study Day 1. * Symptomatic or clinically active brain metastases. * Major surgery within 4 weeks of Study Day 1. * Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease). * Symptomatic coronary artery disease, cerebrovascular accident,transient ischemic attack, myocardial infarction, or unstable angina pectoris within 6 months of Screening.